Late cycle. Medicine ++In November 2023, it was reported that German chemical concern Bayer AG was considering options for splitting the business due to weak financial performance.
Management considered several options:
spinning off the health products or agricultural fertilizer businesses into a separate company;
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.72 USD
−2.76 B USD
50.41 B USD
3.93 B
About BAYER AG NA O.N.
Sector
Industry
CEO
William N. Anderson
Website
Headquarters
Leverkusen
Founded
1952
FIGI
BBG000BYMB76
Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.
Bottom up with clear upside momentumXETR:BAYN Bayer is looking at a possible rebound after the stock rose strongly and attempting to break above the bearish gap seen.
Ichimoku is showing a strong bullish signal and we believe near-term should see further upside.
Long-term MACD is back to the positive. Stochastic confirms the bull
Bayer stock : Contrarian storyBayer stock might be considered a contrarian investment:
Legal overhang from Monsanto acquisition: The ongoing litigation related to the Roundup herbicide has created significant uncertainty and negatively impacted Bayer's stock price. A contrarian investor might see this as an overreaction and bel
Bayer AG Analysis: Growth Potential and Positive Buying SentimenThe history of Bayer AG shares goes through many key moments and events:
Foundation and early years: Bayer was founded in 1863 by Friedrich Bayer and Johann Wagner in Germany. The company initially dealt with the production of chemicals and textile dyes.
Development of aspirin: In 1897, Bayer synt
BAYER AG: $40.60 | Aspirin AlkaSeltzer Monsanto + $11bn Settled Bill Anderson doing the roadshow in Dc and Carlyle Group seems to be
going in heavy at current levels or lower for the next RUN UP
a long game to make a killing for heavy hitters in the pharma bio agri chemical business
the timing to position for such a deal takes time and feel in the this type of
Bayer (BAYN): End of a long 9-year correctionBayer (BAYN): XETR:BAYN
Upon request from one of our members, we're taking a closer look at Bayer AG. We believe that we are still in an overarching Wave II. This wave finds its last true support at the 88.2% retracement level at €24.51. Falling significantly below this level would likely lead
Bayer (BAYN): Is the Bottom Finally Here?Since our initial analysis in November, Bayer's stock has experienced a 40% pullback. Despite missing our limit order by 2%, we have decided to enter the market now and plan to make additional purchases if the price drops further.
The stock has held around the 88.2% Fibonacci retracement level. We
GERMANY STOCK > ( BAYN ) long Based on my graphic analysis I observe a bullish projection of 11% in the price of this corporation, that is; from $28.79 it will rise to $31.96. With a sell exit emerging at $26.47, it is worth remembering that exactly how long the rally will take is unpredictable, the market will simply do its job
Bayer double bottom Bayer was trending down for last almost a year. Now it's seems to draw the double botton. Stock found the support, bounce twice and seems to be recovering. Moreover, the dividend is incomingin near future what could boost the price additionally.
this is not a recomendation, only my guess what could
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
BAYZ4067527
Monsanto Company 4.65% 15-NOV-2043Yield to maturity
9.41%
Maturity date
Nov 15, 2043
BAYZ4230946
Monsanto Company 3.95% 15-APR-2045Yield to maturity
9.29%
Maturity date
Apr 15, 2045
BAYZ4140707
Monsanto Company 4.4% 15-JUL-2044Yield to maturity
9.01%
Maturity date
Jul 15, 2044
BAYZ3875861
Monsanto Company 3.6% 15-JUL-2042Yield to maturity
8.80%
Maturity date
Jul 15, 2042
BAYZ4140706
Monsanto Company 4.7% 15-JUL-2064Yield to maturity
8.57%
Maturity date
Jul 15, 2064
BAYZ4685470
Bayer US Finance II LLC 3.95% 15-APR-2045Yield to maturity
8.34%
Maturity date
Apr 15, 2045
US7274NBG7
BAY.US FI.II. 2045 144AYield to maturity
8.17%
Maturity date
Apr 15, 2045
US7274NBH5
BAY.US FI.II. 2064 144AYield to maturity
7.93%
Maturity date
Jul 15, 2064
US7274NBF9
BAY.US FI.II. 2044 144AYield to maturity
7.80%
Maturity date
Jul 15, 2044
BAYZ4662675
Bayer US Finance II LLC 4.4% 15-JUL-2044Yield to maturity
7.80%
Maturity date
Jul 15, 2044
BAYZ4804053
Bayer US Finance II LLC 3.6% 15-JUL-2042Yield to maturity
7.76%
Maturity date
Jul 15, 2042
See all BAYRY bonds
Curated watchlists where BAYRY is featured.

German Stocks: Continental champs
16 No. of Symbols
See all sparks